ClinicalTrials.gg
RecruitingNCT07182955Updated Sep 19, 2025

Determinants of Cardiorespiratory Fitness and Effects of HIIT in Patients With ANOCA Obstructive Coronary Artery Disease(ANOCA)

An interventional study of EXERCISE TRAINING WITH OR WITHOUT MEDICATION in MINOCA, Shortness of Breath and Atherosclerotic Heart Disease of Native Coronary Artery, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by University of Virginia · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The main goal is to understand what causes reduced fitness in ANOCA and whether targeted exercise can help improve it.

This study aims to better understand why patients with Angina and No Obstructive Coronary Artery Disease (ANOCA) have poor cardiorespiratory fitness and its effect on quality of life.

Investigators also want to see if a structured high-intensity exercise program (HIIT), done with remote monitoring, can safely improve heart function, fitness, and quality of life in these patients. The Investigators will use a special exercise test called cardiopulmonary exercise testing to look for patterns that can help explain exercise limitations and quality of life in ANOCA before and after a remote high-intensity exercise program.

Read the detailed description

The overall research plan is for 25 subjects with angina and no obstructive coronary artery disease (ANOCA) on invasive or coronary CT angiography (ANOCA Study Population) to undergo cardiopulmonary exercise testing (CPET) to assess exercise workload and hemodynamic variables and health-related quality of life (HRQOL) measurement at baseline, followed by repeat testing after high-intensity interval exercise training for 4 weeks. The investigators will examine the diagnostic role of exercise by determining the relationship between exercise fitness and assessing the degree of cardiac, ventilatory, and muscle impairment on CPET.

Anginal burden and related functional status will be assessed via the Seattle Anginal Questionnaire. Overall functional status will be assessed through the Short form (SF36) and MacNew forms, levels of cardiac anxiety through the Cardiac Anxiety Questionnaire (CAQ), and effects on work absenteeism and presenteeism through the Work Limitations Questionnaire (WLQ). Baseline exercise status will be documented through the Duke Activity Status Index form.

The investigators will identify cardiorespiratory fitness peak oxygen consumption (VO2peak) and CPET phenotype with ANOCA. The investigators hypothesize that patients with ANOCA will have reduced VO2 peak and heterogeneous CPET phenotypes with substantial and varying contributions of cardiac, ventilatory, and muscle impairment. Phenotyping of determinants of exercise intolerance will be carried out using the following CPET parameters: cardiac-VO2peak, non-invasive cardiac output with CO2 rebreathing, and O2pulse; ventilatory via VE/VO2and oxygen uptake efficiency slope (OUES); muscle by VE/VCO2 slope, a-vO2 difference, and quadriceps muscle strength on isokinetic dynamometry. The Investigators predict that cardiac impairment will be the most frequent CPET phenotype in ANOCA, and this group will have poor exercise fitness.

The investigators will perform a 4-week high-intensity interval exercise training in 25 patients with ANOCA. The investigators will examine the feasibility of a remote exercise program with ramp exercise thresholds. The investigators predict that exercise program session adherence will be >80% based on preliminary data. The investigators will assess the effect of HIIT on CPET phenotype, improvement in VO2peak in patients with varying CPET phenotypes, model entropy, and HRQOL overall score and specific functional domains. The investigators predict that VO2peak will significantly improve with HIIT.

The exercise protocol for subjects will entail one initial supervised exercise session. All subsequent exercises will be done remotely. Each heart rate monitor will be programmed with heart rate zones that are 85-90% of that subject's angina threshold on the CPET. Subjects will be instructed to start with one 1-minute exercise and one 1-minute rest. The protocol will increase the length of exercise with the goal of getting up to four 4-minute sessions of exercise on three non-consecutive days of the week.

Remote HIIT will be accomplished using Polar heart rate monitoring and the Polar flow application. Patients will receive one supervised, treadmill exercise training session with all other exercise sessions performed remotely (brisk walking).

Participants will be provided with a wrist-based Polar Unite, which measures movement as well as heart rate (green LED) and transmits data to a centralized Polar storage site. Participants will be asked to wear the Polar device every day during the study. In addition, during intervention sessions, participants will be asked to wear the chest stripe to get a more accurate recording of HR to follow the exercise prescription.

Study staff will help set up the Polar watch and Polar Application and will demonstrate how to use them. Subjects will be given one training session in the exercise physiology core lab in which they will be shown how to follow the exercise regimen via their Polar device and also shown how to properly use the equipment.

02

Conditions studied

  • MINOCA
  • Shortness of Breath
  • Atherosclerotic Heart Disease of Native Coronary Artery

Browse trials for

Keywords

  • ANOCA/MINOCA
  • High Intensity Interval Training
  • CPET Phenotype
  • Cardiorespiratory Fitness
03

In context

MINOCA

29 studies on the registry are indexed under MINOCA; 18 are open to participants now.

Browse MINOCA studies →

Lead sponsor

University of Virginia is the lead sponsor of 675 studies on the registry; 138 are open to participants now.

Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-85
  • ANOCA (Anginal symptoms of chest pain or exertional dyspnea suspected to be from myocardial ischemia Invasive or CT coronary angiogram without obstructive epicardial CAD (≥50% left main or ≥70% other epicardial stenosis or fractional flow reserve ≤0.80)
  • Able to use the wearable and participate in a remote exercise program
  • Able to participate in intermittent high-intensity training.
  • Able to perform cardiopulmonary exercise testing (CPET)
  • Able to provide Health-related quality of life questionnaire (HRQOL)
  • Participants must be able to understand and provide in English and complete the study questionnaire in English

Exclusion criteria

Exclusion Criteria:

  • Systolic heart failure ( \<50% or class III symptoms)
  • Prior myocardial infarction, coronary revascularization
  • Inability to safely undergo cardiopulmonary exercise testing, based on investigator's judgment
  • Pregnancy (due to unknown effects on CPET exercise markers)
  • Inability to provide
  • \<1 year
  • Prisoners
  • Cognitively impaired
  • Non-English speaking
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Exercise

    Remote 4 weeks of high-intensity interval exercise training on three non-consecutive days of the week.

    Behavioral: EXERCISE TRAINING WITH OR WITHOUT MEDICATION

Interventions

  • BehavioralEXERCISE TRAINING WITH OR WITHOUT MEDICATION

    Remote 4 weeks of high-intensity interval exercise training on three non-consecutive days of the week.

06

What researchers measure

Primary outcomes

  1. Examine cardiorespiratory fitness (change in VO2max in mL/kg/min) with cardiopulmonary exercise testing (CPET) Phenotype.

    The investigators will assess VO2max (mL/kg/min) in 25 patients with ANOCA at the exercise laboratory.

    Time frame: 4 weeks

Secondary outcomes

  1. Assess Changes in cardio-respiratory fitness (CRF) (VO2max) with High-Intensity Interval Exercise Training (HIIT) in Patients with ANOCA.

    The investigators will examine the feasibility of a remote exercise program using ramp exercise thresholds. Based on preliminary data, they predict that adherence to the exercise sessions will exceed 80%. After four weeks of remote exercise, the investigators will reassess cardiorespiratory fitness (VO2max in mL/kg/min) after the HIIT intervention.

    Time frame: 4 weeks

  2. Health Related Quality Of Life (HRQOL) questionnaire

    The investigators will assess the health-related quality of life at baseline, alongside exercise testing, and again four weeks after the completion of the study to evaluate any changes.

    Time frame: 4 Weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Angadi SS, Jarrett CL, Sherif M, Gaesser GA, Mookadam F. The effect of exercise training on biventricular myocardial strain in heart failure with preserved ejection fraction. ESC Heart Fail. 2017 Aug;4(3):356-359. doi: 10.1002/ehf2.12149. Epub 2017 Mar 16. PubMed 28772048 ↗
  • Hambrecht R, Walther C, Mobius-Winkler S, Gielen S, Linke A, Conradi K, Erbs S, Kluge R, Kendziorra K, Sabri O, Sick P, Schuler G. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004 Mar 23;109(11):1371-8. doi: 10.1161/01.CIR.0000121360.31954.1F. Epub 2004 Mar 8. PubMed 15007010 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07182955
Responsible party
Jamieson Bourque, MD (Professor of Medicine & Radiology, Medical Director of Nuclear Cardiology and Stress Laboratory, Medical Director of Echocardiography, University of Virginia) — Principal investigator
First posted
Sep 19, 2025
Start date
Aug 11, 2025
Primary completion
Mar 30, 2026 (estimated)
Completion
Apr 14, 2026 (estimated)
Last update
Sep 19, 2025

Study contacts

Rahel Askari
Contact
rahel.askari@uvahealth.org
434-243-7195
Jamieson M Bourque, MD, MHS
principal investigator · University of Virginia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion